+

WO2007103134A3 - Prolongation of survival of an allograft by inhibiting complement activity - Google Patents

Prolongation of survival of an allograft by inhibiting complement activity Download PDF

Info

Publication number
WO2007103134A3
WO2007103134A3 PCT/US2007/005290 US2007005290W WO2007103134A3 WO 2007103134 A3 WO2007103134 A3 WO 2007103134A3 US 2007005290 W US2007005290 W US 2007005290W WO 2007103134 A3 WO2007103134 A3 WO 2007103134A3
Authority
WO
WIPO (PCT)
Prior art keywords
allograft
methods
complement activity
survival
prolongation
Prior art date
Application number
PCT/US2007/005290
Other languages
French (fr)
Other versions
WO2007103134A2 (en
Inventor
Russell P Rother
Hao Wang
Zhen Zhong
Original Assignee
Alexion Pharma Inc
Russell P Rother
Hao Wang
Zhen Zhong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38475394&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007103134(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US12/224,567 priority Critical patent/US20100135992A1/en
Priority to EP07752018.7A priority patent/EP1988882B1/en
Priority to BRPI0708424-2A priority patent/BRPI0708424A2/en
Priority to CN200780015830XA priority patent/CN101437501B/en
Priority to KR1020147028450A priority patent/KR101650264B1/en
Priority to RS20150109A priority patent/RS53864B1/en
Priority to ES07752018T priority patent/ES2530637T3/en
Priority to KR1020087023398A priority patent/KR101527225B1/en
Priority to AU2007224250A priority patent/AU2007224250B2/en
Priority to MX2008011054A priority patent/MX2008011054A/en
Priority to SI200731610T priority patent/SI1988882T1/en
Priority to NZ570802A priority patent/NZ570802A/en
Application filed by Alexion Pharma Inc, Russell P Rother, Hao Wang, Zhen Zhong filed Critical Alexion Pharma Inc
Priority to PL07752018T priority patent/PL1988882T3/en
Priority to DK07752018.7T priority patent/DK1988882T3/en
Priority to JP2008557383A priority patent/JP5722524B2/en
Priority to CA2644020A priority patent/CA2644020C/en
Publication of WO2007103134A2 publication Critical patent/WO2007103134A2/en
Priority to IL193623A priority patent/IL193623A0/en
Publication of WO2007103134A3 publication Critical patent/WO2007103134A3/en
Priority to HK09101244.3A priority patent/HK1120444A1/en
Priority to HRP20150182TT priority patent/HRP20150182T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Methods of prolonging survival of allotransplanted cells, tissues or organs are presented. These methods are directed to administering to the allograft recipient an inhibitor of complement activity together with one or more immunosuppressants and/or immunosuppressive methods. The inhibitor of complement activity is administered chronically. These methods have been determined to aid in preventing chronic rejection of allografts. These methods can additionally be used in cases in which the recipient has been presensitized to the allograft or in which there is an ABO mismatch between the allograft and the recipient.
PCT/US2007/005290 2006-03-02 2007-03-02 Prolongation of survival of an allograft by inhibiting complement activity WO2007103134A2 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
CA2644020A CA2644020C (en) 2006-03-02 2007-03-02 Prolongation of survival of an allograft by inhibiting complement activity
SI200731610T SI1988882T1 (en) 2006-03-02 2007-03-02 Prolongation of survival of an allograft by inhibiting complement activity
BRPI0708424-2A BRPI0708424A2 (en) 2006-03-02 2007-03-02 prolongation of survival of an allograft by inhibition of complement activity
CN200780015830XA CN101437501B (en) 2006-03-02 2007-03-02 Prolongation of survival of an allograft by inhibiting complement activity
KR1020147028450A KR101650264B1 (en) 2006-03-02 2007-03-02 Prolongation of survival of an allograft by inhibiting complement activity
RS20150109A RS53864B1 (en) 2006-03-02 2007-03-02 Prolongation of survival of an allograft by inhibiting complement activity
ES07752018T ES2530637T3 (en) 2006-03-02 2007-03-02 Extension of the survival of an allograft by inhibition of complement activity
KR1020087023398A KR101527225B1 (en) 2006-03-02 2007-03-02 Prolonged survival of allografts by inhibiting complement activity
AU2007224250A AU2007224250B2 (en) 2006-03-02 2007-03-02 Prolongation of survival of an allograft by inhibiting complement activity
US12/224,567 US20100135992A1 (en) 2006-03-02 2007-03-02 Prolongation of Survival of an Allograft by Inhibiting Complement Activity
NZ570802A NZ570802A (en) 2006-03-02 2007-03-02 Prolongation of survival of an allograft by inhibiting complement activity
EP07752018.7A EP1988882B1 (en) 2006-03-02 2007-03-02 Prolongation of survival of an allograft by inhibiting complement activity
MX2008011054A MX2008011054A (en) 2006-03-02 2007-03-02 Prolongation of survival of an allograft by inhibiting complement activity.
PL07752018T PL1988882T3 (en) 2006-03-02 2007-03-02 Prolongation of survival of an allograft by inhibiting complement activity
DK07752018.7T DK1988882T3 (en) 2006-03-02 2007-03-02 PROLONGED SURVIVAL OF A allograft by inhibiting complement activity
JP2008557383A JP5722524B2 (en) 2006-03-02 2007-03-02 Prolonging allograft survival by inhibiting complement activity
IL193623A IL193623A0 (en) 2006-03-02 2008-08-21 Prolongation of survival of an allograft by inhibiting complement activity
HK09101244.3A HK1120444A1 (en) 2006-03-02 2009-02-11 Prolongation of survival of an allograft by inhibiting complement activity
HRP20150182TT HRP20150182T1 (en) 2006-03-02 2015-02-16 Prolongation of survival of an allograft by inhibiting complement activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77885906P 2006-03-02 2006-03-02
US60/778,859 2006-03-02

Publications (2)

Publication Number Publication Date
WO2007103134A2 WO2007103134A2 (en) 2007-09-13
WO2007103134A3 true WO2007103134A3 (en) 2008-09-12

Family

ID=38475394

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/005290 WO2007103134A2 (en) 2006-03-02 2007-03-02 Prolongation of survival of an allograft by inhibiting complement activity

Country Status (22)

Country Link
US (1) US20100135992A1 (en)
EP (2) EP1988882B1 (en)
JP (2) JP5722524B2 (en)
KR (2) KR101527225B1 (en)
CN (1) CN101437501B (en)
AU (1) AU2007224250B2 (en)
BR (1) BRPI0708424A2 (en)
CA (1) CA2644020C (en)
DK (1) DK1988882T3 (en)
ES (1) ES2530637T3 (en)
HK (1) HK1120444A1 (en)
HR (1) HRP20150182T1 (en)
IL (1) IL193623A0 (en)
MX (1) MX2008011054A (en)
NZ (1) NZ570802A (en)
PL (1) PL1988882T3 (en)
PT (1) PT1988882E (en)
RS (1) RS53864B1 (en)
RU (1) RU2445975C2 (en)
SG (1) SG171578A1 (en)
SI (1) SI1988882T1 (en)
WO (1) WO2007103134A2 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE066795T2 (en) 2006-03-15 2024-09-28 Alexion Pharma Inc Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
EP3056568B1 (en) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
NZ575018A (en) * 2006-09-05 2012-04-27 Alexion Pharma Inc Compositions for the treatment of antibody mediated neuropathies
ES2831325T3 (en) 2006-10-10 2021-06-08 Regenesance B V Complement inhibition for better nerve regeneration
MX369784B (en) 2007-09-26 2019-11-21 Chugai Pharmaceutical Co Ltd Method of modifying isoelectric point of antibody via amino acid substitution in cdr.
SG10201608379YA (en) 2008-04-11 2016-11-29 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
EP3121197A1 (en) * 2008-11-10 2017-01-25 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
WO2010126898A1 (en) * 2009-04-27 2010-11-04 The Trustees Of The University Of Pennsylvania Methods for reducing the level of alloantibodies in a subject
AU2010264520A1 (en) * 2009-06-23 2012-01-19 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
AU2010266127B2 (en) * 2009-07-02 2015-11-05 Musc Foundation For Research Development Methods of stimulating liver regeneration
CN101621801B (en) * 2009-08-11 2012-11-28 华为终端有限公司 Method, system, server and terminal for authenticating wireless local area network
CN108715614A (en) 2010-11-30 2018-10-30 中外制药株式会社 The antigen binding molecules combined are repeated with polymolecular antigen
KR20140040744A (en) * 2011-05-16 2014-04-03 겐자임 코포레이션 Induction of immune tolerance by using methotrexate
CN102585016B (en) * 2012-03-06 2014-06-04 江苏健德生物药业有限公司 Immune fusion protein capable of inhibiting T and B lymphocyte functions and preparation method and application thereof
CN103232542B (en) * 2013-02-01 2015-05-13 殷勇 Double-target chimeric protein
EP4300103A3 (en) 2013-08-07 2024-02-28 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (ahus) biomarker proteins
EP3033093A1 (en) * 2013-08-16 2016-06-22 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
SMT201900042T1 (en) * 2013-11-22 2019-02-28 Shire Viropharma Inc Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
IL278014B2 (en) 2014-12-19 2023-10-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
WO2016098356A1 (en) 2014-12-19 2016-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use
JP7221691B2 (en) * 2015-10-30 2023-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド Method for inhibiting exacerbation of T cell-mediated allograft vasculopathy
PE20240365A1 (en) * 2015-12-18 2024-03-04 Chugai Pharmaceutical Co Ltd ANTI-C5 ANTIBODIES AND METHODS OF USE
WO2017212391A1 (en) * 2016-06-07 2017-12-14 Novartis Ag An anti-c5 antibody dosing regimen
WO2017212392A1 (en) * 2016-06-07 2017-12-14 Novartis Ag Tesidolumab for use in the treatment of transplant rejection
HUE067224T2 (en) 2016-06-14 2024-10-28 Regeneron Pharma Anti-c5 antibodies and uses thereof
CN116251182A (en) 2016-08-05 2023-06-13 中外制药株式会社 Compositions for preventing or treating IL-8 related diseases
HUE064436T2 (en) 2017-07-27 2024-03-28 Alexion Pharma Inc High concentration anti-c5 antibody formulations
MX2020004284A (en) 2017-10-26 2020-10-28 Alexion Pharma Inc DOSE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR THE TREATMENT OF PAROXYSTIC NOCTURNAL HEMOGLOBINURIA (PNH) AND ATYPICAL HEMOLYTIC UREMIC SYNDROME (HUS).
MX2020006113A (en) 2017-12-13 2020-08-24 Regeneron Pharma Anti-c5 antibody combinations and uses thereof.
CN112996561A (en) 2018-10-30 2021-06-18 亚力兄制药公司 Subcutaneous dosage and administration of anti-C5 antibody for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
CN111449050A (en) * 2019-01-20 2020-07-28 睿诺医疗科技（上海）有限公司 Cyclosporine analogues and their uses
CA3138597A1 (en) 2019-05-10 2020-11-19 The Regents Of The University Of California Modified pluripotent cells
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
WO2021146471A2 (en) * 2020-01-15 2021-07-22 The Regents Of The University Of California Transplanted cell protection via inhibition of polymorphonuclear cells
CN114532982A (en) * 2022-01-12 2022-05-27 高谋 System for evaluating complement activation regulation effect of stem cell system transplantation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992010205A1 (en) * 1990-12-06 1992-06-25 T Cell Sciences, Inc. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
WO2004019891A2 (en) * 2002-08-28 2004-03-11 Sangstat Medical Corporation Methods and compostions for immune tolerance
WO2005110481A2 (en) * 2004-05-14 2005-11-24 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2588579B2 (en) 1988-04-21 1997-03-05 株式会社クラレ Polyvinyl alcohol fiber excellent in hot water resistance and method for producing the same
US5705732A (en) 1989-06-12 1998-01-06 Oklahoma Medical Research Foundation Universal donor cells
US5573940A (en) 1989-06-12 1996-11-12 Oklahoma Medical Research Foundation Cells expressing high levels of CD59
US5135916A (en) 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US20010018051A1 (en) * 1990-04-09 2001-08-30 White David James Graham Inhibition of allograft and concordant xenograft rejection
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) * 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US6355242B1 (en) * 1997-05-23 2002-03-12 Ixion Biotechnology, Inc. Materials and methods for treating or preventing oxalate-related disease
US6280957B1 (en) * 1998-02-04 2001-08-28 The General Hospital Corporation Costimulatory blockade and mixed chimerism in allo-transplantation
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
WO2000027421A2 (en) 1998-11-06 2000-05-18 The Schepens Eye Research Institute, Inc. LOCAL USE OF SOLUBLE TUMOR NECROSIS RECEPTOR I (sTNFRI) FOR PROPHYLAXIS AND TREATMENT OF CORNEAL TRANSPLANT REJECTION AND OTHER DISORDERS OF THE EYE
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
AUPQ431299A0 (en) 1999-11-26 1999-12-23 Unisearch Limited Method of inducing immune tolerance
AU2001234730A1 (en) * 2000-02-01 2001-08-14 Beth Israel Deaconess Medical Center Method for inhibiting complement activation
ES2333775T3 (en) 2000-10-10 2010-03-01 Genentech, Inc. INHIBITION OF THE ACTIVATION OF COMPLEMENT C5 FOR THE TREATMENT AND PREVENTION OF REJECTED XENOINJERTO DELAY OR ACUTE VASCULAR REJECTION.
IL158384A0 (en) * 2001-06-08 2004-05-12 Novartis Ag Treatment or prophylaxis of insulin producing cell graft rejection
CN100391537C (en) 2001-08-17 2008-06-04 建南德克公司 Complement pathway inhibitor that binds to C5 and C5A but does not prevent C5B formation
JP4564261B2 (en) * 2002-01-22 2010-10-20 ジェンザイム、コーポレーション Use of TGF-β antagonists for the treatment and prevention of chronic graft rejection
US7923010B2 (en) * 2003-09-11 2011-04-12 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
MXPA06013463A (en) * 2004-05-17 2007-03-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992010205A1 (en) * 1990-12-06 1992-06-25 T Cell Sciences, Inc. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
WO2004019891A2 (en) * 2002-08-28 2004-03-11 Sangstat Medical Corporation Methods and compostions for immune tolerance
WO2005110481A2 (en) * 2004-05-14 2005-11-24 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CLAVIJO-ALVAREZ ET AL: "Pharmacologic Approaches to Composite Tissue Allograft", THE JOURNAL OF HAND SURGERY, W.B. SAUNDERS, vol. 32, no. 1, 9 January 2007 (2007-01-09), pages 104 - 118, XP005752831, ISSN: 0363-5023 *
PLATT J L ET AL: "THE ROLE OF COMPLEMENT IN TRANSPLANTATION", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 36, 1 January 1999 (1999-01-01), pages 965 - 971, XP002933696, ISSN: 0161-5890 *
SÉVENO CÉLINE ET AL: "Induction of regulatory cells and control of cellular but not vascular rejection by costimulation blockade in hamster-to-rat heart xenotransplantation.", XENOTRANSPLANTATION JAN 2007, vol. 14, no. 1, January 2007 (2007-01-01), pages 25 - 33, XP002486630, ISSN: 0908-665X *
WANG HAO ET AL: "Attenuation of acute xenograft rejection by short-term treatment with LF15-0195 and monoclonal antibody against CD45RB in a rat-to-mouse cardiac transplantation model", TRANSPLANTATION, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 75, no. 9, 15 May 2003 (2003-05-15), pages 1475 - 1481, XP009101984, ISSN: 0041-1337 *
WANG HAO ET AL: "Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibody combined with cyclosporine", TRANSPLANTATION, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 79, no. 9, 1 May 2005 (2005-05-01), pages 1121 - 1127, XP002356730, ISSN: 0041-1337 *
YANG JINMING ET AL: "LF15-0195 generates tolerogenic dendritic cells by suppression of NF-kappaB signaling through inhibition of IKK activity.", JOURNAL OF LEUKOCYTE BIOLOGY SEP 2003, vol. 74, no. 3, September 2003 (2003-09-01), pages 438 - 447, XP002486629, ISSN: 0741-5400 *

Also Published As

Publication number Publication date
CA2644020C (en) 2016-05-10
EP1988882B1 (en) 2014-12-17
KR20140124023A (en) 2014-10-23
BRPI0708424A2 (en) 2011-05-31
EP1988882A2 (en) 2008-11-12
JP5722524B2 (en) 2015-05-20
KR101527225B1 (en) 2015-06-08
RU2445975C2 (en) 2012-03-27
WO2007103134A2 (en) 2007-09-13
HK1120444A1 (en) 2009-04-03
RS53864B1 (en) 2015-08-31
KR20080098543A (en) 2008-11-10
EP2918269A1 (en) 2015-09-16
CA2644020A1 (en) 2007-09-13
JP2013155202A (en) 2013-08-15
CN101437501B (en) 2012-09-05
RU2008139118A (en) 2010-04-10
ES2530637T3 (en) 2015-03-04
PT1988882E (en) 2015-02-17
HRP20150182T1 (en) 2015-06-05
CN101437501A (en) 2009-05-20
PL1988882T3 (en) 2015-04-30
AU2007224250A1 (en) 2007-09-13
SI1988882T1 (en) 2015-07-31
KR101650264B1 (en) 2016-08-22
AU2007224250B2 (en) 2012-05-03
MX2008011054A (en) 2009-03-03
IL193623A0 (en) 2009-08-03
JP2009528369A (en) 2009-08-06
NZ570802A (en) 2012-03-30
SG171578A1 (en) 2011-06-29
DK1988882T3 (en) 2015-02-23
US20100135992A1 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
WO2007103134A3 (en) Prolongation of survival of an allograft by inhibiting complement activity
CA2566716C (en) Prolongation of survival of an allograft by inhibiting complement activity
WO2007095594A3 (en) Methods and compositions for enhancing engraftment of hematopoietic stem cells
WO2005070090A3 (en) Regulatory t cells suppress autoimmunity
WO2007100895A3 (en) Cancer treatment with gamma-secretase inhibitors
WO2008036374A3 (en) Allogeneic stem cell transplants in non-conditioned recipients
WO2006026570A3 (en) Use of stem cells to generate inner ear cells
AU2010308458A8 (en) Orally transformable tablets
NZ617412A (en) Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
WO2008079460A3 (en) Tyrosine kinase inhibitors for prevention or treatment of infection
MX2008011633A (en) Aminoquinolones as gsk-3 inhibitors.
EP2030615A3 (en) Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
WO2009040445A3 (en) Arabinoxylo-oligosaccharides useful against gastrointestinal infections
NZ577393A (en) Use of 3-alpha-androstanediol, optionally in combination with a pde5 inhibitor, in the treatment of sexual dysfunction
WO2009035634A3 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
WO2006086498A3 (en) Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors
TN2009000135A1 (en) Use of modified cyclosporins
WO2006116185A3 (en) Methods for the treatment of multiple myeloma
WO2004100885A3 (en) Compositions and methods for treating cancer
WO2006047841A3 (en) Engineering with homing factors
WO2011029102A3 (en) Cd117+cells and uses thereof
WO2004087045A3 (en) Devices, methods, and compositions to prevent restenosis
SG155939A1 (en) Phosphoindoles as hiv inhibitors
WO2006124904A3 (en) Cancer treatment by combined inhibition of telomerase and hsp90 activities
WO2008008549A3 (en) Combination of an immunosuppressive agent and nonsteroidal anti -inflammatory drugs to treat neoplasia

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 193623

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2644020

Country of ref document: CA

Ref document number: 570802

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2007224250

Country of ref document: AU

Ref document number: MX/A/2008/011054

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 7366/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008557383

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2007752018

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007752018

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007224250

Country of ref document: AU

Date of ref document: 20070302

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020087023398

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2008139118

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200780015830.X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 12224567

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0708424

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080901

WWE Wipo information: entry into national phase

Ref document number: 1020147028450

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: P-2015/0109

Country of ref document: RS

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载